Amarin Corporation plc

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-11 pm EDT 5-day change 1st Jan Change
0.7458 USD -1.67% Intraday chart for Amarin Corporation plc +8.65% -14.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday MT
Amarin Commercial Partner in China Receives Regulatory Approval for Heart Drug Vascepa MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Sector Update: Health Care MT
Amarin Shares Fall After CEO Resignation MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Amarin Names Aaron Berg as Chief Executive Officer MT
Amarin Corporation plc Announces CEO Changes CI
Amarin Corporation plc Announces Executive Changes CI
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading MT
Amarin Says Greece Approves Vazkepa for National Reimbursement; Signs Commercialization Agreement With Vianex MT
Amarin Corporation plc Receives National Reimbursement for Vazkepa (Icosapent Ethyl) in Greece by Greek Ministry of Health CI
Chart Amarin Corporation plc
More charts
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.7458 USD
Average target price
1 USD
Spread / Average Target
+34.08%
Consensus
  1. Stock Market
  2. Equities
  3. AMRN Stock
  4. News Amarin Corporation plc
  5. Sector Update: Health Care Stocks Rise Tuesday Afternoon